NECLIFE
Nectar Lifesciences Limited
Nectar Lifesciences Limited (NECLIFE) financial statements and selected valuation metrics through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
neclife.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Stock price
₹10.54
Market cap
205 Cr
Stock P/E
Loss (TTM EPS ₹-12.48)
P/B
0.35
Dividend yield
0.5%
ROE (FY26)
-50.3%
ROCE (FY26)
-73.2%
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Nectar Lifesciences (NECLIFE) is a former maker of pharmaceutical ingredients and formulations that sold its core pharma business in a slump sale completed in November 2025, and it is now evaluating real estate projects while it winds down its remaining capsule business and asset holdings.
Company snapshot
104thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
Concerns
- ✗Interest coverage of -1.7x — earnings barely cover interest payments, which is a warning sign.
1 more signal from the filings.Sign in free to see them all
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 398 Cr | 452 Cr | 441 Cr | 359 Cr | 428 Cr | 455 Cr | 431 Cr | 281 Cr | 5 Cr | 0 Cr | 0 Cr | 0.01 Cr |
| Operating expenses (approx.) | 371 Cr | 410 Cr | 393 Cr | 319 Cr | 385 Cr | 410 Cr | 585 Cr | 343 Cr | 6 Cr | 2 Cr | 59 Cr | 28 Cr |
| EBITDA | 27 Cr | 42 Cr | 49 Cr | 40 Cr | 43 Cr | 45 Cr | -154 Cr | -62 Cr | -1 Cr | -2 Cr | -59 Cr | -28 Cr |
| OPM % | 6.8% | 9.3% | 11.0% | 11.1% | 10.1% | 9.8% | -35.8% | -22.1% | -20.9% | — | — | -191031.0% |
| Other income | 11 Cr | 0.48 Cr | 1 Cr | 0.55 Cr | 0.69 Cr | 0.57 Cr | 0.08 Cr | 0.35 Cr | 0.74 Cr | 0.66 Cr | 8 Cr | 3 Cr |
| Interest | 21 Cr | 25 Cr | 24 Cr | 20 Cr | 20 Cr | 17 Cr | 18 Cr | 19 Cr | 0 Cr | 30 Cr | 6 Cr | 0.16 Cr |
| Depreciation | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 16 Cr | 16 Cr | 16 Cr | 17 Cr | 0.20 Cr | 0.06 Cr | 0.08 Cr | 0.11 Cr |
| Profit before tax | 2 Cr | 2 Cr | 11 Cr | 5 Cr | 9 Cr | 13 Cr | -188 Cr | -97 Cr | -271 Cr | -40 Cr | -130 Cr | -24 Cr |
| Tax % | 38.1% | 36.2% | 94.7% | 39.6% | 35.4% | 37.5% | 30.7% | 34.6% | 34.9% | 135.7% | 47.8% | 36.2% |
| Net profit | 1 Cr | 2 Cr | 0.59 Cr | 3 Cr | 6 Cr | 8 Cr | -130 Cr | -63 Cr | -176 Cr | 14 Cr | -68 Cr | -15 Cr |
| EPS (₹) | ₹0.05 | ₹0.07 | ₹0.03 | ₹0.13 | ₹0.25 | ₹0.35 | ₹-5.80 | ₹-2.82 | ₹-7.84 | ₹0.64 | ₹-3.38 | ₹-0.79 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,744 Cr | 1,901 Cr | 2,783 Cr | 2,367 Cr | 1,544 Cr | 1,669 Cr | 1,525 Cr | 1,686 Cr | 1,673 Cr | 0 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 1,520 Cr | 1,664 Cr | 2,519 Cr | 2,147 Cr | 1,434 Cr | 1,510 Cr | 1,471 Cr | 1,533 Cr | 1,700 Cr | 61 Cr | Sign in free for the trailing twelve months |
| EBITDA | 224 Cr | 237 Cr | 264 Cr | 220 Cr | 110 Cr | 159 Cr | 54 Cr | 153 Cr | -26 Cr | -61 Cr | Sign in free for the trailing twelve months |
| OPM % | 12.9% | 12.4% | 9.5% | 9.3% | 7.1% | 9.5% | 3.5% | 9.1% | -1.6% | — | Sign in free for the trailing twelve months |
| Other income | 23 Cr | 6 Cr | 6 Cr | 4 Cr | 3 Cr | 11 Cr | 42 Cr | 13 Cr | 2 Cr | 9 Cr | Sign in free for the trailing twelve months |
| Interest | 117 Cr | 115 Cr | 148 Cr | 126 Cr | 112 Cr | 79 Cr | 79 Cr | 87 Cr | 75 Cr | 36 Cr | Sign in free for the trailing twelve months |
| Depreciation | 62 Cr | 64 Cr | 63 Cr | 61 Cr | 60 Cr | 57 Cr | 59 Cr | 61 Cr | 62 Cr | 0.34 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 67 Cr | 63 Cr | 59 Cr | 37 Cr | -85 Cr | 34 Cr | -42 Cr | 18 Cr | -162 Cr | -462 Cr | Sign in free for the trailing twelve months |
| Tax % | 17.9% | 16.6% | 19.1% | 15.2% | 13.6% | 26.5% | 43.0% | 72.7% | 29.6% | 36.6% | Sign in free for the trailing twelve months |
| Net profit | 55 Cr | 52 Cr | 48 Cr | 32 Cr | -73 Cr | 25 Cr | -24 Cr | 5 Cr | -114 Cr | -293 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹2.47 | ₹2.33 | ₹2.12 | ₹1.42 | ₹-3.27 | ₹1.12 | ₹-1.08 | ₹0.22 | ₹-5.07 | ₹-13.40 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | — | — | 0.0% | — | 0.0% | — | — | Sign in free for the trailing twelve months |
Sign in free for the trailing twelve months
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 19 Cr |
| Reserves | 984 Cr | 1,036 Cr | 1,083 Cr | 1,114 Cr | 1,040 Cr | 1,065 Cr | 1,042 Cr | 1,047 Cr | 934 Cr | 563 Cr |
| Borrowings | 794 Cr | 854 Cr | 802 Cr | 741 Cr | 903 Cr | 860 Cr | 754 Cr | 636 Cr | 582 Cr | — |
| Other liabilities | 780 Cr | 811 Cr | 798 Cr | 756 Cr | 423 Cr | 443 Cr | 371 Cr | 486 Cr | 509 Cr | 39 Cr |
| Total liabilities | 2,581 Cr | 2,724 Cr | 2,705 Cr | 2,633 Cr | 2,388 Cr | 2,391 Cr | 2,189 Cr | 2,191 Cr | 2,047 Cr | 622 Cr |
| Fixed assets (net) | 824 Cr | 806 Cr | 786 Cr | 746 Cr | 734 Cr | 680 Cr | 613 Cr | 590 Cr | 577 Cr | 103 Cr |
| CWIP | 102 Cr | 100 Cr | 100 Cr | 115 Cr | 99 Cr | 85 Cr | 78 Cr | 66 Cr | 57 Cr | 0 Cr |
| Investments | 0.68 Cr | 0.78 Cr | 0.78 Cr | 0.40 Cr | 0.69 Cr | 0.69 Cr | 0.55 Cr | 0.73 Cr | 0.76 Cr | 13 Cr |
| Loans & advances | — | — | — | — | — | — | 0.37 Cr | 0.92 Cr | 0.86 Cr | 0.09 Cr |
| Inventories | 855 Cr | 859 Cr | 918 Cr | 978 Cr | 588 Cr | 660 Cr | 673 Cr | 709 Cr | 690 Cr | 0.30 Cr |
| Trade receivables | 500 Cr | 612 Cr | 559 Cr | 396 Cr | 375 Cr | 447 Cr | 280 Cr | 379 Cr | 345 Cr | 0 Cr |
| Cash & bank | 13 Cr | 9 Cr | 21 Cr | 21 Cr | 26 Cr | 18 Cr | 18 Cr | 20 Cr | 19 Cr | 0 Cr |
| Other assets | 287 Cr | 336 Cr | 321 Cr | 378 Cr | 567 Cr | 500 Cr | 528 Cr | 425 Cr | 357 Cr | 505 Cr |
| Total assets | 2,581 Cr | 2,724 Cr | 2,705 Cr | 2,633 Cr | 2,388 Cr | 2,391 Cr | 2,189 Cr | 2,191 Cr | 2,047 Cr | 622 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 199 Cr | 65 Cr | 239 Cr | 285 Cr | 21 Cr | 95 Cr | 134 Cr | 225 Cr | 169 Cr | -349 Cr |
| Cash from investing | -18 Cr | -29 Cr | -26 Cr | -33 Cr | -29 Cr | 17 Cr | 52 Cr | -17 Cr | -42 Cr | 1,208 Cr |
| Cash from financing | -204 Cr | -40 Cr | -201 Cr | -252 Cr | 11 Cr | -119 Cr | -186 Cr | -205 Cr | -128 Cr | -767 Cr |
| Net cash flow | -23 Cr | -4 Cr | 12 Cr | -0.03 Cr | 4 Cr | -8 Cr | -0.23 Cr | 2 Cr | -0.58 Cr | 93 Cr |
| Free cash flow (OCF − Capex) | 145 Cr | 32 Cr | 201 Cr | 230 Cr | -10 Cr | 70 Cr | 104 Cr | 195 Cr | 126 Cr | -361 Cr |
Ratios
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 10.3% | 9.3% | 10.9% | 8.7% | 1.4% | 5.8% | 2.0% | 6.2% | -5.7% | -73.2% |
| ROE % | 5.5% | 4.9% | 4.3% | 2.8% | -6.9% | 2.3% | -2.3% | 0.5% | -11.9% | -50.3% |
| Debtor days | 104 | 117 | 73 | 61 | 88 | 97 | 67 | 82 | 75 | — |
| Inventory days | 274 | 226 | 150 | 195 | 208 | 199 | 204 | 208 | 201 | — |
| Days payable | 170 | 142 | 79 | 105 | 121 | 114 | 97 | 123 | 128 | — |
| Cash conversion cycle | 209 | 201 | 144 | 151 | 175 | 183 | 174 | 167 | 149 | — |
| OCF / EBITDA % | 88.6% | 27.5% | 90.5% | 129.5% | 19.4% | 59.9% | 247.7% | 146.8% | — | — |
| OCF / EBITDA % (3 years) | — | — | 69.4% | 81.8% | 91.8% | 82.1% | 77.5% | 124.0% | 292.3% | n.m. |
| Debt / equity | 0.79 | 0.81 | 0.73 | 0.65 | 0.85 | 0.79 | 0.71 | 0.59 | 0.61 | — |
| Current ratio | 1.17 | 1.27 | 1.28 | 1.29 | 1.04 | 1.35 | 1.38 | 1.32 | 1.21 | 9.71 |
| Net debt / EBITDA | 3.48 | — | — | — | — | — | 13.65 | 4.02 | — | — |